Heron Therapeuti (HRTX) - Total Assets
Based on the latest financial reports, Heron Therapeuti (HRTX) holds total assets worth $246.22 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore HRTX operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Heron Therapeuti - Total Assets Trend (1987–2025)
This chart illustrates how Heron Therapeuti's total assets have evolved over time, based on quarterly financial data. See HRTX net assets for net asset value and shareholders' equity analysis.
Heron Therapeuti - Asset Composition Analysis
Current Asset Composition (December 2025)
Heron Therapeuti's total assets of $246.22 Million consist of 93.0% current assets and 7.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.2% |
| Accounts Receivable | $89.59 Million | 35.0% |
| Inventory | $92.75 Million | 36.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1987–2025)
This chart illustrates how Heron Therapeuti's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HRTX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Heron Therapeuti's current assets represent 93.0% of total assets in 2025, an increase from 78.6% in 1987.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2025, down from 75.7% in 1987.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1987.
- Asset Diversification: The largest asset category is inventory at 36.3% of total assets.
Heron Therapeuti Competitors by Total Assets
Key competitors of Heron Therapeuti based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $260.53 Million |
Heron Therapeuti - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.53 | 2.40 | 4.47 |
| Quick Ratio | 1.51 | 1.76 | 3.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $138.47 Million | $124.28 Million | $284.68 Million |
Heron Therapeuti - Advanced Valuation Insights
This section examines the relationship between Heron Therapeuti's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.18 |
| Latest Market Cap to Assets Ratio | 0.37 |
| Asset Growth Rate (YoY) | 9.7% |
| Total Assets | $255.88 Million |
| Market Capitalization | $95.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Heron Therapeuti's assets below their book value (0.37x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Heron Therapeuti's assets grew by 9.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Heron Therapeuti (1987–2025)
The table below shows the annual total assets of Heron Therapeuti from 1987 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $255.88 Million | +9.75% |
| 2024-12-31 | $233.15 Million | +4.78% |
| 2023-12-31 | $222.51 Million | -11.33% |
| 2022-12-31 | $250.95 Million | -17.91% |
| 2021-12-31 | $305.71 Million | -13.53% |
| 2020-12-31 | $353.56 Million | -31.05% |
| 2019-12-31 | $512.78 Million | +10.95% |
| 2018-12-31 | $462.18 Million | +97.25% |
| 2017-12-31 | $234.31 Million | +247.21% |
| 2016-12-31 | $67.48 Million | -51.05% |
| 2015-12-31 | $137.84 Million | +79.76% |
| 2014-12-31 | $76.68 Million | +0.98% |
| 2013-12-31 | $75.94 Million | +35.67% |
| 2012-12-31 | $55.97 Million | +187.85% |
| 2011-12-31 | $19.45 Million | +567.98% |
| 2010-12-31 | $2.91 Million | -67.48% |
| 2009-12-31 | $8.95 Million | -24.14% |
| 2008-12-31 | $11.80 Million | -68.06% |
| 2007-12-31 | $36.95 Million | +114.19% |
| 2006-12-31 | $17.25 Million | +92.34% |
| 2005-12-31 | $8.97 Million | -47.28% |
| 2004-12-31 | $17.01 Million | +29.33% |
| 2003-12-31 | $13.15 Million | -26.09% |
| 2002-12-31 | $17.80 Million | -24.28% |
| 2001-12-31 | $23.51 Million | -12.92% |
| 2000-12-31 | $27.00 Million | +14.88% |
| 1999-12-31 | $23.50 Million | +1.73% |
| 1998-12-31 | $23.10 Million | -4.55% |
| 1997-12-31 | $24.20 Million | +31.52% |
| 1996-12-31 | $18.40 Million | -20.35% |
| 1995-12-31 | $23.10 Million | -1.70% |
| 1994-12-31 | $23.50 Million | -3.69% |
| 1993-12-31 | $24.40 Million | -13.78% |
| 1992-12-31 | $28.30 Million | +194.79% |
| 1991-12-31 | $9.60 Million | -17.24% |
| 1990-12-31 | $11.60 Million | -12.12% |
| 1989-12-31 | $13.20 Million | -21.43% |
| 1988-12-31 | $16.80 Million | -20.00% |
| 1987-12-31 | $21.00 Million | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more